Catalent in deal to buy gene therapy contract manufacturer Paragon for $1.2B
The deal follows by weeks Thermo Fisher's acquisition, for $1.7 billion, of gene therapy contract manufacturing organization Brammer Bio.
Thermo Fisher to buy gene therapy contract manufacturer Brammer Bio for $1.7B
Brammer specializes in contract services for viral vector-based gene therapies. Panelists at a conference last week stressed the importance of manufacturing for gene therapy investors.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
With $1.7B deal, medtech CRO Greatbatch swells to one of world’s largest
With the $1.7 billion acquisition of CRO and manufacturing company Lake Region Medical, Texas-based CRO Greatbatch has become one of the largest medtech-focused CROs in the world.
Paragon Bioservices raises $13M to expand CRO/CMO work in vaccines, biologics
Paragon Bioservices – a contract research and manufacturing organization, has closed a $13 million round of Series A financing. The Baltimore company’s focused on biologics and vaccine work. The financing was led by NewSpring Capital and Camden Partners. Paragon CEO Marco Chacon described the fundraise as indicative of “an inflection point for the company,” now that […]